Supportive Technologies for the Scaling of Manufactured Islet Replacement Therapies RFA Grant

Supportive Technologies for the Scaling of Manufactured Islet Replacement Therapies RFA Grant

Status: ACTIVE
Funder: Breakthrough T1D ( Formally JDRF International)
Amount: Up to US $600,000
Last Updated: April 23, 2025

Summary

The Breakthrough T1D initiative invites applications for supportive technologies aimed at scaling manufactured islet cell therapies for type 1 diabetes (T1D). This funding opportunity seeks to enhance the efficiency of protocols and address barriers to the implementation of next-generation beta cell replacement therapies. Grants of up to $600,000 over two years will be available to academic and industry partners. Proposals should focus on innovative differentiation processes, scalable production systems, and effective storage solutions, ensuring broader access to islet therapies.

Overview

Breakthrough T1D Request for Applications: Supportive Technologies for the Scaling of Manufactured Islet Replacement Therapies Summary The goal of this funding opportunity is to improve the efficiency of scaling protocols for manufactured islet cell therapies for type 1 diabetes (T1D) via development of supportive technologies tackling one or more of the barriers associated with implementation and expansion of next-generation beta cell replacement therapies. This initiative will award grants to academic investigators and industry partners of up to $600,000.00 over 2 years. Background The ultimate goal of Breakthrough T1D’s Cell Therapy program is to have an islet replacement therapy that is suitable and accessible for everyone living with T1D. Current clinical islet transplantation is efficacious in improving glycemic control and quality of life but is restricted to individuals with severe hypoglycemia and hypoglycemia unawareness. Further advancements are required to expand the benefits of islet transplantation for broader patient populations. There are several barriers to consider for the expansion of these next generation therapies, namely the supply of a manufactured insulin producing cells, the limited survival and engraftment of transplanted cells, and the need for lifelong broad immunosuppressive medication to prevent rejection. Thanks to the efforts of Breakthrough T1D funded researchers, industry partners, and others, there are multiple late preclinical and early clinical programs advancing toward the dismantling of one or more of these barriers. However, as these products move from late preclinical and early clinical stages, significant technological advancements in processes, storage, and access will be required in order to enable the deployment of these therapies at later stages of development and larger scale. For example, considerations for the differentiation processes to generate manufactured islets from pluripotent cells include cost of goods and labor-intensive protocols. These cells display an immature phenotype compared to bona fide primary islets, requiring a period of in vivo maturation to reach fully functional maturity and provide benefit to patients. Increasing the efficiency for generating high quality cells would better support the expanded T1D patient population for next generation therapies. For example, early critical quality attributes that predict successful differentiation are limited. In addition, the banking and storage of manufactured islet cells at late stages of differentiation remains challenging owing to the fragile nature of insulin producing cells, leading to loss in either viability or function. Overall, while great progress has been made in developing promising islet cell therapies utilizing renewable cell sources, pro-engraftment strategies, and alternative immune protection schemes, there is a need to develop supporting technologies to enable the scaling of these next generation therapies. Funding Opportunity Scope Breakthrough T1D’s role is to enable the scientific community to address these challenges with the ultimate goal of accelerating the development of safe and effective islet cell therapies that are available to all individuals living with established T1D. Therefore, Breakthrough T1D is soliciting Letters of Intent (LOI) from investigators in academic and industry settings aiming to develop supportive technologies tackling one or more of the barriers associated with adoption of next-generation beta cell replacement therapies and enable the scaling of islet cell therapies for expanded patient populations. Examples of topics pertinent to this call include but are not limited to: Validation of novel differentiation processes resulting in shorter timelines to insulin-producing cells.Development of innovative culture systems for scalable production capacity of pluripotent cell differentiation (e.g., automation) Cell culture processes and technologies that reduce the cost of goods for generating insulin-producing cells.Demonstration of cryoprotective storage solutions for manufactured islets that preserve cell viability and glucose responsive insulin secretion.Identification and validation of critical quality attributes at early stages of differentiation that can predict a successful manufactured run or the applicability of a given protocol to a new cell source.

Eligibility

You can learn more about this opportunity by visiting the funder's website. Applications may be submitted by domestic and foreign non-profit organization, public and private, such as universities, colleges, hospitals and laboratories, units of state and local governments and eligible agencies of the federal government, for-profit entities, or industry collaborations with academia. Applicants must hold an M.D., D.M.D., D.V.M., Ph.D., or equivalent and have a faculty position or equivalent at a college, university, medical school, or other research facility.Please note that applications from for-profit entities or industry collaborations with academia may be submitted in response to this RFA. Additional information will be requested from for-profit entities if invited to submit a full proposal.There are no citizenship requirements for this program. Funding MechanismsIn response to this announcement, Letters of Intent (LOI) can be submitted under the following mechanism(s):Strategic Research Agreements (SRAs)Strategic Research Agreements are intended for support of research activities at non-for profit entities such as academic institutions. For SRAs, proposed budgets for projects should not exceed $600,000.00 USD (including 10% indirect costs) total costs for up to two (2) years. The level of funding will vary depending on the scope, data available, need to perform additional laboratory assays, access to samples, degree of data analysis to be performed, and overall objectives of the proposal.If your project budget and/or timeline exceeds $600,000.00 and/or 2 years, please discuss with Breakthrough T1D staff.Industry Discovery and Development Partnerships (IDDPs)For-profit entities may apply under Breakthrough T1D’s Industry Discovery & Development Partnership (IDDP) funding mechanism, which entails additional requirements and typically has a modest royalty payback to Breakthrough T1D. If you would like to submit an Industry Discovery and Development Partnership (IDDP) project LOI to this RFA, please check our grant handbook for additional information and contact Dr. Nicholas Mamrak (nmamrak@BT1D.org) to discuss proposed scope and budget prior to submitting an application. An approved LOI is required prior to the submission of a full proposal.

Ineligibility

Topics out of scope for this funding opportunity:Discovery stage research on immune protection or pro-engraftment strategies Derivative improvements of current protocols at small scale. Projects must demonstrate improvement is transferable to larger scales (e.g., ~1x109 cells per batch). Indirect costs are not permitted on IDDP applications.